First Human Test of CRISPR Proposed
By Antonio Regalado,
MIT Technology Review
| 06. 16. 2016
A federal safety board next week will consider the first human use of the gene-editing technology CRISPR, according to the National Institutes of Health.
The proposed treatment is an immune therapy in which a patient’s own blood cells will be removed and genetically altered using the technology, a type of molecular scissors able to precisely cut DNA.
The cancer treatment, in development by the University of Pennsylvania, is designed to target myeloma, melanoma, and sarcomas, according to the NIH.
Continue reading on MIT Technology Review
Image via Flickr
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Evelina Johansson Wilén, Jacobin | 01.18.2026
In her book The Argonauts, Maggie Nelson describes pregnancy as an experience marked by a peculiar duality. On the one hand, it is deeply transformative, bodily alien, sometimes almost incomprehensible to the person undergoing it. On the other hand...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...